Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Demers, Louise
Oremus, Mark
Perrault, Anne
Champoux, Nathalie
and
Wolfson, Christina
2000.
Review of Outcome Measurement Instruments in Alzheimer's Disease Drug Trials: Psychometric Properties of Functional and Quality of Life Scales.
Journal of Geriatric Psychiatry and Neurology,
Vol. 13,
Issue. 4,
p.
170.
Winblad, Bengt
2001.
Maintaining Functional and Behavioral Abilities in Alzheimer Disease.
Alzheimer Disease & Associated Disorders,
Vol. 15,
Issue. ,
p.
S34.
Coyle, Joseph
and
Kershaw, Paul
2001.
Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer’s disease.
Biological Psychiatry,
Vol. 49,
Issue. 3,
p.
289.
Fodero, Lisa R.
and
Small, David H.
2002.
Cholinergic abnormalities in Alzheimer's disease: are there new targets for drug development?.
Drug Development Research,
Vol. 56,
Issue. 3,
p.
369.
Potkin, Steven G
Anand, Ravi
Hartman, Richard
Veach, Jeffrey
and
Grossberg, George
2002.
Impact of Alzheimer's disease and rivastigmine treatment on activities of daily living over the course of mild to moderately severe disease.
Progress in Neuro-Psychopharmacology and Biological Psychiatry,
Vol. 26,
Issue. 4,
p.
713.
Tabert, M. H.
Albert, S. M.
Borukhova-Milov, L.
Camacho, Y.
Pelton, G.
Liu, X.
Stern, Y.
and
Devanand, D. P.
2002.
Functional deficits in patients with mild cognitive impairment.
Neurology,
Vol. 58,
Issue. 5,
p.
758.
Zhao, Qinying
Brett, Martin
van Osselaer, Nancy
Huang, Fenglei
Raoult, Alain
van Peer, Achiel
Verhaeghe, Tom
and
Hust, Rita
2002.
Galantamine Pharmacokinetics, Safety, and Tolerability Profiles Are Similar in Healthy Caucasian and Japanese Subjects.
The Journal of Clinical Pharmacology,
Vol. 42,
Issue. 9,
p.
1002.
Zhao, Qinying
Iyer, Ganesh R.
Verhaeghe, Tom
and
Truyen, Luc
2002.
Pharmacokinetics and Safety of Galantamine in Subjects with Hepatic Impairment and Healthy Volunteers.
The Journal of Clinical Pharmacology,
Vol. 42,
Issue. 4,
p.
428.
Hock, Christoph
Konietzko, Uwe
Streffer, Johannes R
Tracy, Jay
Signorell, Andri
Müller-Tillmanns, Britta
Lemke, Ulrike
Henke, Katharina
Moritz, Eva
Garcia, Esmeralda
Wollmer, M.Axel
Umbricht, Daniel
de Quervain, Dominique J.F
Hofmann, Marc
Maddalena, Alessia
Papassotiropoulos, Andreas
and
Nitsch, Roger M
2003.
Antibodies against β-Amyloid Slow Cognitive Decline in Alzheimer's Disease.
Neuron,
Vol. 38,
Issue. 4,
p.
547.
Boyle, Patricia A.
Malloy, Paul F.
Salloway, Stephen
Cahn-Weiner, Deborah A.
Cohen, Ronald
and
Cummings, Jeffrey L.
2003.
Executive Dysfunction and Apathy Predict Functional Impairment in Alzheimer Disease.
The American Journal of Geriatric Psychiatry,
Vol. 11,
Issue. 2,
p.
214.
Lindeboom, R.
Vermeulen, M.
Holman, R.
and
De Haan, R. J.
2003.
Activities of daily living instruments.
Neurology,
Vol. 60,
Issue. 5,
p.
738.
Kurz, X.
Scuvee‐Moreau, J.
Rive, B.
and
Dresse, A.
2003.
A new approach to the qualitative evaluation of functional disability in dementia.
International Journal of Geriatric Psychiatry,
Vol. 18,
Issue. 11,
p.
1050.
Bullock, Roger
2004.
The Needs of the Caregiver in the Long-Term Treatment of Alzheimer Disease.
Alzheimer Disease & Associated Disorders,
Vol. 18,
Issue. ,
p.
S17.
Boyle, Patricia A.
2004.
Assessing and predicting functional impairment in Alzheimer’s disease: The emerging role of frontal system dysfunction.
Current Psychiatry Reports,
Vol. 6,
Issue. 1,
p.
20.
Tasker, Andrea
Perry, Elaine K
and
Ballard, Clive G
2005.
Butyrylcholinesterase: impact on symptoms and progression of cognitive impairment.
Expert Review of Neurotherapeutics,
Vol. 5,
Issue. 1,
p.
101.
Bayer, A. J.
Bullock, R.
Jones, R. W.
Wilkinson, D.
Paterson, K. R.
Jenkins, L.
Millais, S. B.
and
Donoghue, S.
2005.
Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD.
Neurology,
Vol. 64,
Issue. 1,
p.
94.
Bullock, R.
and
Dengiz, A.
2005.
Cognitive performance in patients with Alzheimer's disease receiving cholinesterase inhibitors for up to 5 years.
International Journal of Clinical Practice,
Vol. 59,
Issue. 7,
p.
817.
Theotoka, Ioulia
Kapaki, Elisabeth
Vagenas, Vasileios
Ilias, Ioannis
Paraskevas, George P.
and
Liappas, Ioannis
2007.
Preliminary Report of a Validation Study of Instrumental Activities of Daily Living in a Greek Sample.
Perceptual and Motor Skills,
Vol. 104,
Issue. 3,
p.
958.
Castilla‐Rilo, Juan
López‐Arrieta, Jesús
Bermejo‐Pareja, Felix
Ruiz, Miguel
Sánchez‐Sánchez, Fernando
and
Trincado, Rocío
2007.
Instrumental activities of daily living in the screening of dementia in population studies: a systematic review and meta‐analysis.
International Journal of Geriatric Psychiatry,
Vol. 22,
Issue. 9,
p.
829.
Carthery-Goulart, Maria Tereza
Areza-Fegyveres, Renata
Schultz, Rodrigo R.
Okamoto, Ivan
Caramelli, Paulo
Bertolucci, Paulo Henrique F.
and
Nitrini, Ricardo
2007.
Adaptação transcultural da escala de avaliação de incapacidade em demência (Disability Assessment For Dementia - DAD).
Arquivos de Neuro-Psiquiatria,
Vol. 65,
Issue. 3b,
p.
916.